INTERLEUKIN GENETICS INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2009-10-30: Form 8-K; Period of report 2009-10-26; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2009-07-08: Form 8-K; Period of report 2009-07-01; Description 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; Details 1.01.
- 2009-06-04: Form 8-K; Period of report 2009-05-29; Description 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Details 2.03.
- 2009-05-15: Form 8-K; Period of report 2009-05-11; Description 2.02 Results of Operations and Financial Condition; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2009-10-30 | 8-K | 2009-10-26 | 1.01 Entry into a Material Definitive Agreement | 1.01 On October 26, 2009, Interleukin Genetics, Inc. (the “Company”) entered into a Merchant Network and Channel Partner Agreement (the “Agreement”) with Amway Corp. d/b/a Amway Global (“Amway Global”), a subsidiary of Alticor Inc. Pursuant to this Agreement, Amway Global will sell the Company’s Inherent Health™ brand of genetic tests through its e-commerce Web site via a hyperlink to the Company’s e-commerce site. | a09-32585_18k.htm |
| 2009-07-08 | 8-K | 2009-07-01 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets | 1.01 Prior to the opening of business on July 1, 2009, Interleukin Genetics, Inc. (“Interleukin”, “we”, “our”, “us”) and our wholly-owned subsidiary, AJG Brands, Inc. entered into an asset purchase agreement with Nutraceutical Corporation and Pep Products, Inc., a wholly owned subsidiary of Nutraceutical Corporation, pursuant to which we sold substantially all of the Alan James Group business and assets of AJG Brands, Inc. to Pep Products, Inc. for an aggregate sale price of approximately $4.6 million in cash. 2.01 The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 2.01 by reference. | a09-17622_18k.htm |
| 2009-06-04 | 8-K | 2009-05-29 | 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 2.03 On May 29, 2009, Interleukin Genetics, Inc. (“we”, “our”, “us”) elected to draw down $1.0 million under our existing convertible credit facility (described below) with Pyxis Innovations Inc. (“Pyxis”), an affiliate of Alticor Inc., and issued a convertible promissory note to Pyxis in that amount. | a09-14866_18k.htm |
| 2009-05-15 | 8-K | 2009-05-11 | 2.02 Results of Operations and Financial Condition; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 2.02 On May 14, 2009, Interleukin Genetics, Inc. (the “Company”) issued a press release to report its consolidated financial results for its fiscal quarter ended March 31, 2009. 3.01 On January 27, 2009, the Company issued a press release disclosing that it had submitted a plan to NYSE Amex LLC (the “Exchange”), which outlines the actions the Company has taken, or will take, to regain compliance with the continued listing standards set forth in Section 1003(a)(iii) of the Exchange’s Company Guide by June 23, 2010 (the “Compliance Period”). | a09-13612_18k.htm |
| 2009-03-31 | 8-K | 2009-03-27 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 Interleukin Genetics, Inc. (the “Company”) filed a Current Report on Form 8-K with the Securities and Exchange Commission (the “Commission”) on January 27, 2009 to disclose that the Company had submitted a plan to NYSE Amex (the “Exchange”), which outlines the actions the Company has taken, or will take, to regain compliance with the continued listing standards set forth in Section 1003(a)(iii) of the Exchange’s Company Guide by June 23, 2010 (the “Compliance Period”). | a09-8976_18k.htm |
| 2009-03-13 | 8-K | 2009-03-11 | 1.01 Entry into a Material Definitive Agreement | 1.01 On March 11, 2009, Interleukin Genetics, Inc. (the “Company”) entered into an amended and restated note purchase agreement, dated as of March 10, 2009, with Pyxis Innovations Inc., a majority stockholder of the Company (“Pyxis”), to extend the availability of the credit facility described below until March 31, 2010. | a09-7321_28k.htm |
| 2009-03-10 | 8-K | 2009-03-09 | 2.02 Results of Operations and Financial Condition | 2.02 On March 9, 2009, Interleukin Genetics, Inc. issued a press release to report its consolidated financial results for its fiscal year and quarter ended December 31, 2008. | a09-7321_18k.htm |
| 2009-01-15 | 8-K | 2009-01-15 | 8.01 Other Events | 8.01 Interleukin Genetics, Inc. (the “Company”) has been granted an extension by NYSE Alternext US LLC (the “Exchange”) for submitting a plan, advising the Exchange of the actions the Company has taken, or will take, that would bring it into compliance with the continued listing standards as set forth in Part 10 of the Exchange’s Company Guide, from the original deadline of January 23, 2009, until January 30, 2009. | a09-3304_18k.htm |